Noncoding RNA blockade of autophagy is therapeutic in medullary thyroid cancer

Cancer Medicine

Volumn 4, Issue 2, 2015, Pages 174-182

  Gundara, Justin S ^a,b   Zhao, Jingting ^a   Gill, Anthony J ^b   Lee, James C ^a,b   Delbridge, Leigh ^b   Robinson, Bruce G ^a,c   Mclean, Catriona ^d   Serpell, Jonathan ^d   Sidhu, Stan B ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Autophagamir; Autophagy; Medullary; MiR 9 3p; MTC; Oncophagy

Indexed keywords

BECLIN 1; CHLOROQUINE; MESSENGER RNA; MICRORNA; MICRORNA 9 3P; RAPAMYCIN; SMALL INTERFERING RNA; TUMOR MARKER; UNCLASSIFIED DRUG; UNTRANSLATED RNA; APOPTOSIS REGULATORY PROTEIN; ATG5 PROTEIN, HUMAN; BECN1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; MIRN92 MICRORNA, HUMAN;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER PROGNOSIS; CELL CYCLE PROGRESSION; CELL VIABILITY ASSAY; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDULLARY THYROID CARCINOMA CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID MEDULLARY CARCINOMA; CARCINOMA; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MINIMAL RESIDUAL DISEASE; THYROID TUMOR; TUMOR CELL LINE;

APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CARCINOMA, NEUROENDOCRINE; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN VITRO TECHNIQUES; MEMBRANE PROTEINS; MICRORNAS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM, RESIDUAL; THYROID NEOPLASMS;

EID: 84964695449     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.355     Document Type: Article

References (35)

1. Monson, J. P. 2000. The epidemiology of endocrine tumours. Endocr. Relat. Cancer 7:29-36.
2. Hu, M. I., and G. J. Cote . 2012. Medullary thyroid carcinoma: who's on first? Thyroid 22:451-453.
3. Gibb, E. A., C. J. Brown, and W. L. Lam . 2011. The functional role of long non-coding RNA in human carcinomas. Mol. Cancer 10:38.
4. Nana-Sinkam, S. P., and C. M. Croce . 2013. Clinical applications for microRNAs in cancer. Clin. Pharmacol. Ther. 93:98-104.
5. Cho, W. C. S. 2007. OncomiRs: the discovery and progress of microRNAs in cancers. Mol. Cancer 6:60.
6. Esquela-Kerscher, A., and F. J. Slack . 2006. Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer 6:259-269.
7. Abraham, D., N. Jackson, J. S. Gundara, J. Zhao, A. J. Gill, L. Delbridge, et al. 2011. MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin. Cancer Res. 17:4772-4781.
8. Zawistowski, J. S., K. Nakamura, J. S. Parker, D. A. Granger, B. T. Golitz, and G. L. Johnson . 2013. MicroRNA 9-3p targets beta1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition. Mol. Cell. Biol. 33:2260-2274.
9. Okamoto, H., Y. Matsumi, Y. Hoshikawa, K. Takubo, G. Ryoke, and K. Shiota . 2012. Involvement of microRNAs in regulation of osteoblastic differentiation in mouse induced pluripotent stem cells. PLoS One 7:e43800.
10. Gundara, J. S., J. Zhao, B. G. Robinson, and S. B. Sidhu . 2012. Oncophagy-harnessing miRNA regulation of autophagy in cancer therapy. Endocr. Relat. Cancer 18:18.
11. Kebebew, E., F. S. Greenspan, O. H. Clark, K. A. Woeber, and J. Grunwell . 2005. Extent of disease and practice patterns for medullary thyroid cancer. J. Am. Coll. Surg. 200:890-896.
12. Roman, S., R. Lin, and J. A. Sosa . 2006. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134-2142.
13. Gerlinger, M., A. J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, E. Gronroos, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366:883-892.
14. Park, S. T., H.-J. Byun, B.-R. Kim, S. M. Dong, S. H. Park, P. R. Jang, et al. 2013. Tumor suppressor BLU promotes paclitaxel antitumor activity by inducing apoptosis through the down-regulation of Bcl-2 expression in tumorigenesis. Biochem. Biophys. Res. Commun. 435:153-159.
15. Gundara, J., B. Robinson, and S. Sidhu . 2011. Evolution of the "autophagamiR". Autophagy 7:12.
16. Xu, J., Y. Wang, X. Tan, and H. Jing . 2012. MicroRNAs in autophagy and their emerging roles in crosstalk with apoptosis. Autophagy 8:873-882.
17. Lin, C.-I., E. E. Whang, J. H. Lorch, and D. T. Ruan . 2012. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer. Surgery 152:1142-1149.
18. Xu, S., and Z. Weihua . 2011. Loss of EGFR induced autophagy sensitizes hormone refractory prostate cancer cells to adriamycin. Prostate 71:1216-1224.
19. Calabretta, B., and P. Salomoni . 2011. Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors. Leuk. Lymphoma 52(Suppl. 1):54-59.
20. Xie, B.-S., H.-C. Zhao, S.-K. Yao, D.-X. Zhuo, B. Jin, D.-C. Lv, et al. 2011. Autophagy inhibition enhances etoposide-induced cell death in human hepatoma G2 cells. Int. J. Mol. Med. 27:599-606.
21. Gupta, A., S. Roy, A. J. F. Lazar, W.-L. Wang, J. C. McAuliffe, D. Reynoso, et al. 2010. Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc. Natl. Acad. Sci. USA 107:14333-14338.
22. Han, W., J. Sun, L. Feng, K. Wang, D. Li, Q. Pan, et al. 2011. Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells. PLoS One 6:e28491.
23. Shen, S., O. Kepp, and G. Kroemer . 2012. The end of autophagic cell death? Autophagy 8:1-3.
24. Rubinstein, A. D., and A. Kimchi . 2012. Life in the balance-a mechanistic view of the crosstalk between autophagy and apoptosis. J. Cell Sci. 125:5259-5268.
25. Myung Park, J., S. Huang, T.-T. Wu, N. R. Foster, and F. A. Sinicrope . 2013. Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. Cancer Biol. Ther. 14:100-107.
26. Yu, M., W.-F. Gou, S. Zhao, L.-J. Xiao, X.-Y. Mao, Y.-N. Xing, et al. 2013. Beclin 1 expression is an independent prognostic factor for gastric carcinomas. Tumour Biol. 34:1071-1083.
27. Cheng, H. Y., Y. N. Zhang, Q. L. Wu, X. M. Sun, J. R. Sun, and X. Huang . 2012. Expression of beclin 1, an autophagy-related protein, in human cervical carcinoma and its clinical significance. Eur. J. Gynaecol. Oncol. 33:15-20.
28. Karpathiou, G., E. Sivridis, M. Koukourakis, D. Mikroulis, D. Bouros, M. Froudarakis, et al. 2013. Autophagy and Bcl-2/BNIP3 death regulatory pathway in non-small cell lung carcinomas. APMIS 121:592-604.
29. Liang, L.-Z., B. Ma, Y.-J. Liang, H. C. Liu, G. S. Zheng, T. H. Zhang, et al. 2012. High expression of the autophagy gene Beclin-1 is associated with favorable prognosis for salivary gland adenoid cystic carcinoma. J. Oral Pathol. Med. 41:621-629.
30. Chen, Y., Y. Lu, C. Lu, and L. Zhang . 2009. Beclin-1 expression is a predictor of clinical outcome in patients with esophageal squamous cell carcinoma and correlated to hypoxia-inducible factor (HIF)-1alpha expression. Pathol. Oncol. Res. 15:487-493.
31. Pan, X., X. Zhang, H. Sun, J. Zhang, M. Yan, and H. Zhang . 2013. Autophagy inhibition promotes 5-fluorouraci-induced apoptosis by stimulating ROS formation in human non-small cell lung cancer A549 cells. PLoS One 8:e56679.
32. Gong, C., C. Bauvy, G. Tonelli, W. Yue, C. Deloménie, V. Nicolas, et al. 2013. Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells. Oncogene 32:2261-2272.
33. Del Bello, B., M. Toscano, D. Moretti, and E. Maellaro . 2013. Cisplatin-induced apoptosis inhibits autophagy, which acts as a pro-survival mechanism in human melanoma cells. PLoS One 8:e57236.
34. Zhang, H.-Y., Z.-X. Du, X. Meng, Z. H. Zong, and H. Q. Wang . 2013. Beclin 1 enhances proteasome inhibition-mediated cytotoxicity of thyroid cancer cells in macroautophagy-independent manner. J. Clin. Endocrinol. Metab. 98:E217-E226.
35. Anderson, K. C. 2013. Therapeutic advances in relapsed or refractory multiple myeloma. J. Natl. Compr. Canc. Netw. 11:676-679.